Eribulin in combination with bevacizumab as secondline treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) (vol 6, 100054, 2021)